NEW YORK CITY (dpa-AFX) - The FDA has required the manufacturers of the RSV Vaccines Abrysvo and Arexvy to add a new warning to their labels about the potential risk of Guillain-Barré Syndrome ...

(RTTNews) - The FDA has required the manufacturers of the RSV Vaccines Abrysvo and Arexvy to add a new warning to their labels about the potential risk of Guillain-Barré Syndrome following ...

The risks flagged in the prescribing information of GSK’s Arexvy and Pfizer’s Abrysvo are not the regulator’s strictest “boxed” warnings, Reuters says. Published first on TheFly – the ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window The ...

LONDON, Jan. 8, 2025 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT) a leading global provider of transformative intelligence, today announced the release of the twelfth annual Drugs to Watch™ report, a ...

A post-marketing review by the FDA detected an increased risk of the autoimmune condition in patients inoculated with GSK’s Arexvy and Pfizer’s Abrysvo, prompting the regulator to require adjustments ...

The agency also reaffirmed that the benefits of both Pfizer’s Abrysvo and GSK’s Arexvy outweigh their risks. The new labeling is based on postmarketing monitoring for GBS in older adults who received ...

The FDA has required and approved safety labeling changes to the Prescribing Information for Abrysvo manufactured by US giant Pfizer (NYSE: PFE) and Arexvy from the UK’s GSK (LSE: GSK). Specifically, ...

Según los últimos datos publicados por el Instituto Nacional de Estadística de España (INE), hay —al menos hasta enero de 2024— 415.987 personas nacidas en la Argentina que residen en ...

Compounding pharmacies must now cease producing their own versions of Zepbound/Mounjaro within a set time period. HealthDay News — The U.S. Food and Drug Administration re-issued a decision first made ...

Arexvy contains an adjuvant while Abrysvo does not. “When we compared the antibody responses between those study participants who received Arexvy with those who got Abrysvo, we found that the group ...